TRIPLE THERAPY IN COPD: A GAME-CHANGER? - EXAMINING ETHOS, IMPACT &TRIBUTE STUDIES

Abstract

 Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease affecting millions worldwide. In recent years, the use of triple therapy, which combines an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), has most recommended for the management of COPD. Triple therapy has been shown to improve lung function, reduce exacerbations, and improve quality of life compared to other treatments, especially in patients with more severe COPD. This study aims to compare dual therapies and triple therapies according to the pivot studies namely IMPACT, TRIBUTE, and ETHOS. This review shows the safety and effectiveness of triple therapy. However, as with any medication, there are potential side effects and risks associated with triple therapy, and it is important for healthcare providers to carefully consider each patient's individual needs and risks before prescribing this treatment. Overall, triple therapy has emerged as a valuable treatment option for patients with COPD.